Biotech Bulls: Baxalta Incorporated (NYSE:BXLT), NantKwest (NASDAQ:NK), Incyte Corporation (NASDAQ:INCY), Trevena, Inc. (NASDAQ:TRVN), Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS)

Baxalta Incorporated (NYSE: BXLT) confirmed receipt from Shire plc (LSE: SHP, NASDAQ: SHPG) of a highly conditional, unsolicited proposal to acquire all of the outstanding common shares of Baxalta in an all-stock transaction under which Baxalta shareholders would receive for each Baxalta share 0.1687 Shire ADRs.Baxalta Incorporated (NYSE:BXLT) belongs to Healthcare sector. Its weekly performance is 21.88%. On last trading day company shares ended up $37.10. Baxalta Incorporated (NYSE:BXLT) distance from 50-day simple moving average (SMA50) is 16.62%.

On 28 July, NantKwest, Inc. (NASDAQ:NK), a clinical-stage immunotherapy company focused on harnessing the power of the innate immune system by using the natural killer cell to treat cancer, infectious diseases and inflammatory diseases, announced the pricing of its initial public offering of 8,288,000 shares of its common stock at a price to the public of $25.00 per share. NantKwest (NASDAQ:NK) shares increased 8.46% in last trading session and ended the day at $30.00.

Incyte Corporation (NASDAQ:INCY) reported Net income for the quarter ended June 30, 2015 was $9 million, or $0.05 per basic and diluted share, as compared to a net loss of $37 million, or $0.22 per basic and diluted share, for the same period in 2014. Net loss for the six months ended June 30, 2015 was $9 million, or $0.05 per basic and diluted share as compared to a net loss of $71 million, or $0.43 per basic and diluted share, for the same period in 2014.On 04 August, Incyte Corporation (NASDAQ:INCY) shares increased 5.54% and was closed at $109.74. INCY EPS growth in last 5 year was 32.40%. Incyte Corporation (NASDAQ:INCY) year to date (YTD) performance is 50.10%.

Trevena, Inc. (NASDAQ:TRVN), announced that Maxine Gowen, Ph.D., chief executive officer, will present a company overview at the 2015 Wedbush PacGrow Healthcare Conference on Tuesday, August 11, 2015 at 3:40 p.m. EDT in New York. Trevena, Inc. (NASDAQ:TRVN) ended the last trading day at $6.53. Company weekly volatility is calculated as 6.10% and price to cash ratio as 2.55. Trevena, Inc. (NASDAQ:TRVN) showed a weekly performance of 4.82%.

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) reported net losses of $5.3 million and $12.3 million for the three and six months ended June 30, 2015, respectively. Our cash used in operating activities was $9.2 million for the six months ended June 30, 2015 compared to $3.5 million for the same period a year ago.Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) shares increased 11.32% in last trading session and ended the day at $19.38. MRNS return on assets is -44.50%. Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) quarterly performance is 158.40%.

Leave a Reply

Your email address will not be published. Required fields are marked *